Galera Therapeutics completes acquisition of Nova Pharmaceuticals
December 31, 2024 07:00 ET
|
Galera Therapeutics
Galera’s development strategy shifts from toxicity reduction to anti-cancer therapeutics, with three trials in patients with highly resistant subsets of advanced breast cancer. Lead program is...
Galera Announces Board Approval of Complete Liquidation and Dissolution
August 14, 2024 07:00 ET
|
Galera Therapeutics
MALVERN, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company historically focused on developing a pipeline of novel,...
Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates
May 13, 2024 07:00 ET
|
Galera Therapeutics
Galera's First Quarter 2024 Earnings Release
Galera Adopts Limited Duration Stockholder Rights Agreement
May 03, 2024 07:00 ET
|
Galera Therapeutics
MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the...
Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates
March 28, 2024 07:00 ET
|
Galera Therapeutics
MALVERN, Pa., March 28, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have...
Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
November 14, 2023 07:00 ET
|
Galera Therapeutics
FDA confirms need for new trial for avasopasem; GRECO trials with rucosopasem to be discontinued Company evaluating potential strategic options to optimize shareholder value MALVERN, Pa., Nov. 14,...
Galera Announces Receipt of Type A Meeting Minutes and Strategic Update
October 31, 2023 07:00 ET
|
Galera Therapeutics
FDA confirms need for new trial for avasopasem for severe oral mucositis (SOM) GRECO-2 trial did not pass futility analysis; Company will discontinue both GRECO trials Company reviewing potential...
Galera Schedules Type A Meeting with FDA to Discuss Next Steps for Avasopasem
September 18, 2023 07:00 ET
|
Galera Therapeutics
MALVERN, Pa., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
Galera to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
September 05, 2023 07:00 ET
|
Galera Therapeutics
MALVERN, Pa., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
Galera Reports Second Quarter 2023 Financial Results and Recent Corporate Updates
August 14, 2023 07:00 ET
|
Galera Therapeutics
Company received Complete Response Letter from FDA for avasopasem and intends to request Type A meeting with FDA to discuss potential next steps Cash runway extended into Q2 2024 in connection with...